We count visits as totals without cookies, and never follow you from one day to the next. If you accept, we also use cookies to see how people use this site, so we can improve it. Privacy policy
Last close (USD)68.63+0.51 (+0.75%)as of 4 Nov 2026
Funds that hold it1One fund per scheme
Held through a master fund10 buy the stock themselves
Largest weight in a single fund2.37%Of that fund's NAV
Median weight2.37%Half the funds hold more than this
What does PTCT do
PTC Therapeutics, Inc.
Develops drugs for rare diseases, especially genetic diseases in children. Most revenue comes from drug sales and royalties from partners
TranslarnaEmflazaUpstaza (gene therapy)Royalties from pharmaceutical partners
Which funds let you invest in PTCT
Sorted by weight held, largest first
Investors in Thailand can buy PTCT through 1 mutual funds open to retail investors. Most of them (1 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds PTCT.
Showing 1 of 1 funds you can buy · The full list is in the Expert view · Latest weights from portfolio reports, and funds can change their portfolios at any time · Past performance is not a guarantee of future performance
PTCT share price
0.00%
Price change over the selected periodN/A
50-day average
200-day average
Valuation and key ratios
PTC Therapeutics, Inc. · NASDAQ · Fiscal year ends in January
Market cap5.7B USD0.08 billion shares
P/E8.8xPrice ÷ FY2025 EPS 7.78
Forward P/E22.2xBased on forecast 12-month earnings
P/S4.9x
EV/EBITDA20.6x
Dividend yield0.00%0.00 USD per share a year
ROE−104.7%Net profit ÷ shareholders' equity
Debt to equity (D/E)−1.40xInterest-bearing debt
Beta0.52Against the S&P 500
Gross marginN/AFY2025
Operating margin50.1%FY2025
Net margin39.5%FY2025
Price ratios use the latest close shown on this page · Forward P/E, P/S and EV/EBITDA from Market data · Beta from 5 years of monthly returns · Total dividends over the last 12 months
Company health made simple
From the FY2025 statements
Sales growth33.9%Fast growth
Yearly average over the last 4 years · Latest annual sales 1.7B USD
Profit from sales39%Highly profitable
For every 100 dollars of sales, about 39 dollars is left as net profit
Dividend0.00%No dividend
Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits
1-year share price+1.3%Up
Now 23.4% below its 1-year high
A rise or fall in the share price doesn't move a fund by the same amount — a fund is affected only in proportion to how much it holds
Financial statements
Revenue grows 33.9% a year on average · EPS grows N/A a year on average
Annual · last 5 fiscal years
Revenue and net profit
FY2021539.0M USD−524.0M USD
FY2022699.0M USD−559.0M USD
FY2023938.0M USD−627.0M USD
FY2024807.0M USD−363.0M USD
FY20251.7B USD683.0M USD
Total revenue
Net profit
Quarterly · last 5 quarters
Revenue and net profit
Q2 FY2025179.0M USD−65.0M USD
Q3 FY2025211.0M USD16.0M USD
Q4 FY2025165.0M USD−135.0M USD
Q1 FY2026273.0M USD−3.0M USD
Q2 FY2026361.0M USD83.0M USD
Total revenue
Net profit
Annual income statement, balance sheet and cash flow
Item (USD)
FY2021
FY2022
FY2023
FY2024
FY2025
Total revenue
539.0M USD
699.0M USD
938.0M USD
807.0M USD
1.7B USD
Operating profit
−374.0M USD
−447.0M USD
−440.0M USD
−303.0M USD
867.0M USD
Net profit
−524.0M USD
−559.0M USD
−627.0M USD
−363.0M USD
683.0M USD
EPS (diluted)
−7.43
−7.79
−8.37
−4.73
7.78
Operating margin
−69.4%
−63.9%
−46.9%
−37.5%
50.1%
Net margin
−97.2%
−80.0%
−66.8%
−45.0%
39.5%
Operating cash flow
−251.0M USD
−357.0M USD
−158.0M USD
−108.0M USD
711.0M USD
Free cash flow
−280.0M USD
−389.0M USD
−187.0M USD
−114.0M USD
702.0M USD
Total assets
1.9B USD
1.7B USD
1.9B USD
1.7B USD
2.9B USD
Total liabilities
1.9B USD
2.1B USD
2.7B USD
2.8B USD
3.1B USD
Shareholders' equity
1.0M USD
−347.0M USD
−818.0M USD
−1.1B USD
−205.0M USD
Free cash flow = operating cash flow − capital expenditure · A cell showing N/A is an item the statement doesn't report, not a zero · Source: SEC EDGAR
Technical analysis
Closed at 68.63 USD on 4 Nov 2026
Daily trendClear uptrendScore 0.80 on a scale of −1 to +1 · 1255 bars
RSI(14)
61.2
ADX(14)
18.1
Position in the price range
61%
Weekly trendLeaning upScore 0.30 on a scale of −1 to +1 · 262 bars
RSI(14)
50.8
ADX(14)
20.2
Position in the price range
31%
Monthly trendClear uptrendScore 0.83 on a scale of −1 to +1 · 61 bars
RSI(14)
55.4
ADX(14)
25.9
Position in the price range
71%
Moving averages (daily)
Period
SMA
EMA
Price vs line
10 days
63.19
63.99
Above
20 days
62.45
63.45
Above
50 days
65.03
65.28
Above
100 days
71.15
67.85
Below
200 days
70.56
68.45
Below
Indicators (daily)
Indicator
Value
Signal
RSI(14)
61.17
Up
MACD(12,26)
0.11
Up
ADX(14)
18.12
Neutral
ATR(14) % of price
2.49
Neutral
Support and resistance (weekly pivots)
s354
s257
s158
p61
r163
r266
r367
Trend score = average of the moving-average group and the indicator group ((up signals − down signals) ÷ number of signals) · RSI and ATR use Wilder's method · MACD uses the 12- and 26-period EMA · An ADX of 25 or above counts as a clear trend · Calculated from daily closing prices from Market data · Not investment advice
Thai funds holding PTCT
1 funds · Highest 2.37% · Median 2.37%
How the weights are spread
Number of funds by weight range
0
1
0
0
0
0
< 1%1–3%3–5%5–8%8–12%12%+
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
One fund counted per scheme · Funds investing through a master fund show the master fund's weight in PTCT, not the look-through weight · Past performance is not a guarantee of future performance
How Thai money reaches PTCT
1 master funds
Master fund
Thai funds using this route
Master fund's PTCT weight
several master funds (JHHBIU2 LX, ARKG US)
1
2.37%
Data sourcesFunds that buy the stock themselves: top 5 holdings from the AMC's fact sheet as of 30 Sep 2026 · Funds that invest through a master fund: the master fund's portfolio from its issuer's fact sheet or prospectus · Each scheme counts as one fund · Share price: Market data · Financial statements: SEC EDGAR · Ratios: Market data · Weights are as of the report date, and funds can change their portfolios at any time · Investing involves risk. This is not investment advice.
ASP-IHEALTHAsset Plus Innovative Healthcare Fund